Back to search results

A Study of TAK-360 for Narcolepsy Type 2

This study is testing a medication called TAK-360 for adults with Narcolepsy Type 2 (NT2). NT2 is a condition that causes extreme daytime sleepiness, even after a full night's rest. TAK-360 works by acting like orexin, a natural brain chemical that helps you stay awake and alert. Researchers want to see if TAK-360 can help reduce sleepiness in people with NT2. The main goal is to check for any side effects of TAK-360 over about 15 weeks. You might be able to join if you are between 18 and 70 years old, weigh at least 40 kg, and have a confirmed diagnosis of NT2. The study plans to enroll 88 participants.

Study design
This study is testing TAK-360 against a placebo (an inactive tablet) in 88 participants. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 15 weeks to monitor for any treatment-emergent adverse events (side effects).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06952699

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

Recruiting
PHASE2Ages 18–70InterventionalTreatment
Takeda
~88 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:TAK-360Placebo

At a glance

Recruiting sites
48 of 52 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Measured over Up to 15 Weeks

Conditions

Narcolepsy Type 2

Explore related trials

Narcolepsy without Cataplexy

Where it's being run

52 sites across 35 states
Florida7
Texas5
California3
North Carolina3
Michigan2
Ohio2
Tokyo2
Alabama1

Study leadership

  • Study Director · STUDY_DIRECTOR · Takeda

Who to contact

Takeda Contact
[email protected]
+1-877-825-3327
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)Up to 15 Weeks

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.